ROTEM-Guided PCC Dosing Targets Post-Bypass Bleeding After High-Risk Cardiac Surgery
High-risk cardiac surgery can leave surgeons and anesthesiologists facing a familiar problem in a narrow window: bleeding after cardiopulmonary bypass when conventional clotting pathways are still disrupted and the chest tube output starts to climb. The University of Miami is preparing a randomized pilot trial to test whether ROTEM-guided dosing of four-factor prothrombin complex concentrate can improve perioperative bleeding control compared with clinician-directed dosing in adults who develop post-bypass coagulopathic bleeding.
The study is built around a practical question with immediate bedside consequences. If viscoelastic testing can identify the coagulation defect more precisely than conventional judgment alone, then replacement therapy may be tailored more efficiently, with less unnecessary factor exposure and better hemostasis in the hours after surgery.
Why Post-Bypass Coagulopathy Demands Faster Coagulation Assessment
Cardiopulmonary bypass alters hemostasis through several mechanisms at once: dilution of clotting factors, platelet dysfunction, consumption of coagulation proteins, and inflammatory activation that can leave the blood in a fragile, poorly coordinated state. In this setting, post-operative bleeding is not just a nuisance; it can trigger transfusion escalation, delayed extubation, re-exploration, prolonged intensive care, and worse recovery trajectories.
The trial focuses on a population already defined as high risk. Eligible adults must be undergoing one or more of several complex procedures: redo cardiac surgery, combined valve surgery and coronary artery bypass grafting, aortic root or ascending aortic surgery, operations requiring hypothermic circulatory arrest, or surgery performed after recent active anticoagulation with a vitamin K antagonist, direct oral anticoagulant, or therapeutic heparin or low-molecular-weight heparin within five days of surgery. After bypass termination, participants must have clinically significant coagulopathic bleeding requiring coagulation factor replacement, with the attending clinician deciding to administer 4F-PCC intraoperatively.
In that narrow clinical interval, the decision to give factor replacement is both urgent and imprecise. ROTEM aims to make the coagulation defect visible in real time.
The Trial Compares an Algorithm to Bedside Judgment
This is a randomized, parallel-assignment, open-label study with an estimated enrollment of 70 participants. The intervention arm uses baseline and post-cardiopulmonary bypass ROTEM assessments to determine initial 4F-PCC dosing through a prespecified algorithm keyed to clotting time prolongation relative to baseline. Doses range from 10 to 50 IU/kg, and subsequent adjustments follow post-treatment ROTEM results through a sequential response-guided strategy. Additional PCC may still be given if the clinician believes it is clinically indicated.
The active comparator arm is more conventional. There, 4F-PCC dosing is determined by the attending cardiac anesthesiologist or cardiac surgeon using clinical assessment and available laboratory results, without a protocol-mandated ROTEM trigger or dosing algorithm. In both arms, the same drug is used, and the difference lies in how the dose is selected.
This design is not about whether 4F-PCC works in principle. It is about whether a point-of-care viscoelastic readout can guide a more efficient and effective hemostatic response than standard decision-making alone.
Chest Tube Output Is the Primary Endpoint
The primary outcome is total 24-hour chest tube drainage volume, measured from surgical closure through 24 hours after surgery. A between-group reduction of 400 mL is considered clinically meaningful. For postoperative cardiac care, that threshold is not trivial. Chest tube output is a direct surrogate for whether the clotting environment has stabilized enough to limit ongoing surgical and coagulopathic bleeding.
A single sentence captures the trial’s central wager: a more precise factor-replacement strategy may reduce bleeding enough to matter at the bedside.
The secondary outcomes extend beyond raw drainage volume. Investigators will measure unplanned return to the operating room within 24 hours for hemorrhage or cardiac tamponade, total 4F-PCC dose administered over the first 24 postoperative hours, and transfusion requirements for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate. The study also tracks duration of mechanical ventilation, intensive care unit length of stay, and 30-day all-cause mortality.
Those endpoints matter because coagulation control after bypass influences more than the drain canister. Bleeding control can determine whether a patient wakes with a stable respiratory course or remains intubated longer, whether ICU discharge is delayed, and whether transfusion burden multiplies in the first postoperative day.
Safety Guardrails Reflect the Thrombotic Risk of Factor Replacement
4F-PCC replaces vitamin K–dependent clotting factors quickly, which is exactly why it can be useful when bleeding is brisk. The same biologic efficiency raises concern for thrombosis, especially in a cardiac surgical population already vulnerable to endothelial injury, altered flow, and perioperative prothrombotic shifts.
The exclusion criteria reflect that risk profile. Patients with known hypersensitivity to PCC, heparin, or any component of the formulation are excluded, as are those with documented heparin-induced thrombocytopenia. The study also excludes active thromboembolic events within three months of surgery when they are not related to the index procedure, pregnancy, participation in another interventional trial within 30 days, life expectancy under 30 days from a non-cardiac cause, and refusal of blood products that would preclude PCC administration.
These exclusions are clinically coherent. A trial asking whether targeted factor replacement improves bleeding must avoid stacking avoidable thrombotic risk on top of an already high-risk surgical substrate.
What the Pilot Can and Cannot Answer
The estimated sample size of 70 makes this a pilot effort rather than a definitive outcomes trial. The design can test feasibility, signal strength, and operational performance of the ROTEM-guided dosing approach, but it will not settle every question about bleeding, thrombosis, or long-term recovery. The absence of masking also leaves room for treatment-adjacent decision-making to influence downstream care, even when the protocol is carefully defined.
Still, the structure is clinically grounded. ROTEM is an FDA-cleared point-of-care coagulation monitoring device, and its use here is paired with a drug already embedded in perioperative blood management. The question is whether tailoring 4F-PCC to a measured clotting abnormality can produce cleaner hemostasis than relying on clinician judgment and standard laboratory results alone.
The trial is scheduled to begin in December 2026, with primary completion and study completion both estimated for November 2027 at the University of Miami Hospital in Miami. Until those data arrive, the study stands as a focused attempt to bring more precision to one of cardiac surgery’s most consequential perioperative decisions: how much clotting factor to give when the chest is still bleeding after bypass.